Professional Experience

Bioinformatics Scientist III (Team Leader)

  • Directed development of scalable, cloud-native workflows for germline variant discovery (SNVs, Indels, CNVs, SVs) using DRAGEN and GATK
  • Led migration to DRAGEN-based pipelines on Illumina Cloud Analytics (ICA), improving performance and clinical alignment
  • Architected a centralized, access-controlled data platform, replacing distributed multi-bucket storage systems
  • Designed structured genomics data models (BigQuery) enabling cohort-level querying and downstream analytics
  • Established best practices for reproducibility and cross-program coordination
  • Oversaw HIPAA-compliant data governance and cost-optimized storage strategies; mentored team members

Bioinformatics Scientist II

  • Developed and deployed genomics workflows in AWS and GCP for sequencing and SNP-array data
  • Partnered with research teams to enable scalable data access and analysis

Postdoctoral Research Associate

  • Somatic short variant discovery (SNVs and Indels) using GATK pipelines on genomic and transcriptomic data
  • Analyzed next- and third-generation sequencing data (RNA-seq) for expression and alternative splicing
  • Integrated, visualized, and interpreted transcriptomic data across immunotherapy-relapsed and chemo-resistant samples
  • Developed and maintained reproducible data analysis workflows and pipelines

Postdoctoral Fellow

  • Developed and optimized Oxford Nanopore long-read sequencing methods for validation of de-novo and artefactual isoforms
  • Functionally characterized splicing-derived isoforms using CRISPR-Cas9 and antisense-oligo splice switching in in-vitro and in-vivo models
  • Implemented ChIP protocols and analyzed ChIP-seq data supporting mechanistic studies of splicing regulation
  • Mined RNA-seq data from immune-relapsed samples with in-vitro validation of splicing factors

PhD Researcher

  • Identified genetic alterations in members of the MYC axis in lung carcinomas
  • Characterized their role in deregulating chromatin-remodeling complexes and oncogenic transcriptional programs
  • Modeled therapeutic opportunities in vitro and in vivo based on synthetic-lethality studies
  • Analyzed WES, RNA-seq, ChIP-seq, and microarray expression data

Education

PhD, Biomedicine

University of Barcelona, 2018

MSc, Advanced Genetics

Autonomous University of Barcelona, 2012

BSc, Molecular Biology

University of Santiago de Compostela, 2011

Technical Skills

Sequencing & Genomics

Illumina (WGS, WES, SNP arrays, RNA-seq, ChIP-seq), Oxford Nanopore long-read sequencing, variant discovery (SNVs, Indels, CNVs, SVs)

Bioinformatics Tools

GATK, DRAGEN, BWA, Bowtie, STAR, Snakemake, Nextflow, WDL, rMATS, MAJIQ, DESeq2, Minimap2, Flair, HOMER, MACS2

Programming & Data

Python, R, Bash, SQL (BigQuery, Presto, AWS Athena)

Cloud & Infrastructure

AWS, GCP, Illumina Cloud Analytics (ICA), HIPAA-compliant data governance

Selected Presentations

  • ASHG Annual Meeting (2024)
  • Torres-Diz M, Reglero-Gomez C, et al. — ASH Annual Meeting (2022): "Non-canonical exon usage in pediatric leukemia: implications for chemoresistance"
  • Torres-Diz M — Catalyzing Cures for Children with Cancer, FusOnC2 & PI-DDN Joint Meeting (2021): "Non-canonical exon usage in pediatric leukemia: implications for chemoresistance"
  • Llabata P, Torres-Diz M, et al. — IASLC (2019): "DNA-Binding and Gene Expression Profiles in Max Deficient Small Cell Lung Cancer"
  • Llabata P, Torres-Diz M, et al. — IASLC (2017): "MGA Suppresses the MYC Pathway in Lung Adenocarcinoma"
  • Romero OA, Torres-Diz M, et al. — AACR Annual Meeting (2014): "MAX Inactivation in Small Cell Lung Cancer Disrupts the MYC-SWI/SNF Programs and Is Synthetic Lethal with BRG1"
  • Torres-Diz M, Romero OA, et al. — 14th International Congress Aseica (2013): "Involvement of MAX in Small Cell Lung Cancer Development"

Publications

My peer-reviewed research record is listed in full on the Publications page →

Interested in working together?

Reach out at info@acceleragenomics.com.

Get In Touch